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The risk of end-stage renal disease (ESRD) remains high in
patients with type 1 diabetes and proteinuria; however, little
is known about the rate of decline in their renal function. To
help determine this, we enrolled patients with type 1 diabetes
and proteinuria whose estimated glomerular filtration rate
(eGFR) was normal (equal to or above 60ml/min per 1.73m2).
Using a minimum of five serial measurements of serum
creatinine for 161 patients, we determined individual
trajectories of eGFR change and the occurrence of ESRD
during 5–18 years of follow-up. The rates were linear for 110
patients, for 24 the nonlinear rate was mild enough to satisfy
a linear model, and the rates were clearly nonlinear for only
27 patients. Overall, in more than one-third of patients, the
eGFR decline was less than 3.5ml/min per 1.73m2 per year
and the lifetime risk of ESRD could be considered negligible.
In the remainder of patients, eGFR declined with widely
different slopes and ESRD developed within 2 to 18 years.
Based on up to 5 years observation, when renal function was
within the normal range, the estimates of early eGFR slope
predicted the risk of ESRD during subsequent follow-up
better than the baseline clinical characteristics of glycated
hemoglobin, blood pressure, or the albumin to creatinine
ratio. Thus, the early slope of eGFR decline in patients with
type 1 diabetes and proteinuria can be used to predict the
risk of ESRD.
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In our recent follow-up study, we found that patients with
Type 1 Diabetes (T1D) and proteinuria are at high risk
of end-stage renal disease (ESRD) despite nearly universal
reno-protective treatment.1 In those with normal serum
creatinine–based estimated glomerular filtration rate (eGFR
X60 ml/min per 1.73 m2) at enrollment, the 15-year risk of
ESRD wasB25%. FinnDiane study investigators2 reported a
similar risk of ESRD in a comparable cohort.
Knowledge of the course of renal function changes in
patients with proteinuria due to diabetes is limited. At one
extreme of possible trajectories is a pattern with episodic
declines of renal function that is referred to as intermittent
episodes of acute renal failure by some authors.3 Such a
pattern would suggest the involvement of stochastic processes
that defy prediction of the time until the onset of ESRD. At
the other extreme is a pattern with a constant rate of decline
in renal function. This pattern was first demonstrated
empirically in a group of 34 individuals with various renal
conditions.4 Subsequent study of nine individuals with
diabetes and impaired renal function confirmed the linearity
of the decline, although there was large inter-individual
variation.5 Other early studies reported a linear GFR decline,
but follow-up was short and study groups were small.6–8
As suggested by these examples, the shape of the
trajectories over time and how it varies among patients
may provide important clues about the mechanisms that
underlie progression to ESRD. A stochastic process suggests a
role of environmental triggers, and identification of their
nature calls for a particular type of study design. A constant
decline, on the other hand, suggests a constitutive determi-
nant and calls for a different type of study design. For
example, a genetic factor would be detectable when renal
function is still in the normal range. Moreover, a constant
slope implies that determination of the early slope while renal
function is normal could predict the late slope and, therefore,
the risk of ESRD.
No prior study of patients with T1D and proteinuria has
traced complete trajectories of renal function changes from
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normal to ESRD. This report traces complete trajectories of
renal function change in the Joslin cohort of patients with
T1D and proteinuria who were followed for 5 to 18 years.1
Three questions guided the analysis. What patterns of
trajectories of renal function changes occur in this popula-
tion? If linear, how varied are the overall slopes of change
during follow-up? To what extent can the early slope of eGFR
decline predict ESRD?
RESULTS
Characteristics of the study group
The study group comprised patients with T1D and
proteinuria who were enrolled into the Joslin Proteinuria
Cohort study between 1991 and 2004 and followed through
2008.1 All were of European ancestry. This study was
restricted to 244 patients with normal renal function (eGFR
X60 ml/min) at enrollment. In the initial analysis to
determine patterns of trajectories of renal function changes,
we used 161 patients (66% of the study group) who had at
least five measurements (range 5–73) of serum creatinine (see
Materials and Methods). Clinical characteristics of patients
with frequent and less frequent measurements of serum
creatinine are summarized in Table 1. Those with less than
five had shorter follow-up and a lower number of creatinine
measurements per year. Otherwise, the two subgroups had
very similar clinical characteristics; therefore, we concluded
that the patterns of trajectories of renal function changes in
those with frequent creatinine measurements were represen-
tative of all 244 patients. All 244 patients were used for
extracting the linear component of each trajectory to
generate a distribution of slopes of overall eGFR change
during follow-up. For evaluating the early slope of eGFR
values as a predictor of ESRD risk, 28 had insufficient early
eGFR measurements for estimating an early slope (see
Materials and Methods) and the remaining 216 were used.
Patterns of trajectories of renal function changes
The first step in the characterization of the trajectories was to
determine whether they were linear or nonlinear. For this
determination we modified an approach described by Jones
and Molitoris9 and used by Shah and Levey,10 to test for non-
linearity of an individual’s renal function changes during
follow-up. The approach requires a minimum of five
observations, so this analysis was limited to the 161 patients
with five or more determinations of eGFR. It represents each
patient’s renal function trajectory as a simple linear model
and as a spline model with linear segments connected at an
individually determined point. Our modification was to allow
more than two segments (three segments were required in two
patients and five segments in one individual). The spline and
linear models were compared, and a linear model was rejected
at a nominal significance of 0.05 and degrees of freedom
determined by the number of spline segments (n1).
The second step in the characterization of the trajectories
was to classify the patient’s eGFR as stable or declining
during follow-up. Our criterion for this distinction was based
on overall slope of eGFR decline. A slope less steep than
3.5 ml/min per 1.73 m2 per year was considered ‘stable’
Table 1 | Characteristics of the study group according to number of serum creatinine measurements
Number of serum creatinine determinations during follow-up
Characteristic Total group, N=244 X5 Measurements, N=161 o5 Measurements, N=83 P-valuea
At baseline
Men (%) 56.6 55.9 57.8 0.77
Age (years) 36.8±8.4 36.9±8.6 36.6±8.0 0.78
Diabetes duration (years) 24.1±8.2 23.8±8.2 24.6±8.4 0.45
Age at diagnosis (years) 12.8±8.0 13.2±8.5 12.0±7.1 0.25
Urinary ACR (mg/g) 676 (430, 1238) 682 (434, 1300) 637 (396, 1156) 0.45
Hemoglobin A1c (%) 9.0±1.7 9.1±1.6 8.9±1.9 0.34
Systolic blood pressure (mmHg) 131±18 132±18 131±16 0.62
Diastolic blood pressure (mmHg) 78±10 78±10 79±9 0.22
ACE-I or ARB treatment (%) 66.0 65.8 66.3 0.95
eGFR (ml/min per 1.73m2) 95±19 95±19 95±19 0.97
Body mass index (kg/m2) 26.7±5.8 26.8±6.3 26.6±5.6 0.86
Total cholesterol (mg/dl) 212.2±49.0 212.6±52.7 212.0±47.2 0.92
HDL cholesterol (mg/dl) 55.3±17.4 59.1±19.6 53.4±15.9 0.02
Statin treatment (%) 17.2 19.3 16.2 0.54
Current smoking (%) 26.9 29.1 22.5 0.28
During follow-up
Length of follow-up (years) 7.4 (5.5, 12.2) 9.0 (6.1, 13.3) 6.2 (4.6, 8.9) —
Creatinine measurements (N) 7.5 (4, 18) 13 (8, 22) 3 (2, 4) —
Creatinines per year (N) 1.1 (0.5, 1.9) 1.6 (1.0, 2.4) 0.5 (0.3, 0.6) —
Incidence rate of ESRDb 2.4 (51) 2.1 (33) 3.2 (18) 0.12
Mortality rate unrelated to ESRDb 0.8 (18) 0.7 (12) 1.1 (6) 0.47
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ACR, albumin to creatinine ratio; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate;
ESRD, end-stage renal disease; HDL, high-density lipoprotein.
Data are percent, mean±s.d. or median (25th, 75th percentile).
aP-value is for the comparison between patients with o5 measurements and those with X5 measurements.
bPer 100 person-years (number of events).
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(Figure 1a–c), while a steeper slope was considered clinically
significant decline (Figure 1d–f). See Materials and Methods
for the motivation underlying this criterion.
The third step in the characterization applied only to
individuals with significantly nonlinear trajectories and was
based on the clinical consequences of the deviations from
linearity. For individuals with stable renal function, we
concluded that the deviations from linearity had no clinical
consequence (Figure 1c). For patients with declining renal
function, the nonlinearity of a trajectory was considered
clinically inconsequential (Figure 1e) if the estimated time of
reaching eGFR¼ 10 ml/min per 1.73 m2 (expected time of
ESRD) was within 1 year of the observed time of ESRD
(vertical dotted line). If the difference was larger, the
nonlinearity of the trajectory was considered clinically
consequential. These nonlinear trajectories were further
characterized as decelerating (Figure 1g) or accelerating (Figure
1h and i). Typically, acceleration interrupted a period of stable
renal function (new-onset decline), as in Figure 1h. Figure 1I
illustrates a rare pattern, acceleration from one rate of decline
to a faster one. Neither acceleration nor deceleration was
significantly associated with renin–angiotensin system blockade.
The frequencies of these different patterns are summarized
in Table 2. The trajectories of 110 patients (68.3%) were
adequately fitted by a simple linear model, 59 stables (36.6%)
and 51 (31.7%) declining. The trajectories for another 24
(14.9%) were significantly nonlinear, but the nonlinearity
was clinically inconsequential, 16 stables (9.9%) and 8
declining (5.0%). Thus, for clinical purposes, a linear model
adequately represented the trajectories of a total of 134
patients (83%). The nonlinearity of the trajectories for the
remaining 27 (17%) patients was clinically consequential, 20
(12.4%) experiencing deceleration and 7 (4.4%) experiencing
acceleration.
Inter-individual variation in trajectories of renal function
changes
To gain an appreciation of the distribution of the overall rate
of eGFR decline in the whole group of 244 subjects, we
extracted the linear component of each trajectory as a simple
slope (Figure 2). A few individuals had a positive slope, i.e.,
improved in renal function at the end of follow-up (n¼ 25),
but the majority had negative slopes, i.e., declining
renal function. The median (25th, 75th percentiles) was
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Figure 1 | Examples of observed patterns of renal function decline. The patterns are: (a, b) linear trajectories, stable renal function;
(c) stable renal function, clinically inconsequential nonlinear trajectory; (d, f) linear decliners; (e) decliner with clinically inconsequential
nonlinear trajectory (observed time of ESRD is within 1 year from the time of reaching eGFR¼ 10 under linear model); (g–i) nonlinear
decline; (g) deceleration; (h) new-onset decline (acceleration); (i) acceleration. Dots represent single eGFR measurements and solid lines
represent linear spline function. Dotted line represents linear regression. Vertical dotted lines mark the observed time of ESRD onset. eGFR,
estimated glomerular filtration rate; ESRD, end-stage renal disease.
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2.9 (7.1, 1.27) ml/min per 1.73 m2 per year. Reflecting
the long tail of negative values, the 5th percentile was 16.8
and the minimum 70.5 ml/min per 1.73 m2 per year. The
fastest eGFR decline is shown in Figure 1f. The available
clinical information for this patient did not indicate any
other cause of renal function decline than T1D (see
Supplementary Appendix 1 for more details).
Exclusion of the slope estimates for patients with
nonlinear or unknown trajectories did not materially change
the shape of the distribution of slopes (insert in Figure 2) or
the median (2.6 as compared with 2.9 ml/min per 1.73 m2
per year).
Prediction of ESRD risk from the early eGFR slope
The observation that a simple linear model of renal function
decline gave satisfactory predictions of renal outcomes for
most patients prompted the question whether data obtained
during early follow-up provide useful prognostic informa-
tion. When a T1D patient presents with proteinuria and
normal renal function, monitoring of eGFR will generally
begin. We sought to examine how well a slope fitted to these
early determinations of eGFR predicts the risk of ESRD. To
mimic this situation, we restricted the measurements to the
first 5 years of follow-up and those made while patients
remained in chronic kidney disease (CKD) stages 1 or 2
(eGFR X60 ml/min per 1.73 m2). Only 216 patients had
at least two serum creatinine measurements for estimating a
slope that met these restrictions. The median early slope was
3.8 ml/min per 1.73 m2 per year, and it did not differ
significantly from the median slope estimated from complete
follow-up (P¼ 0.45). The 25th and 75th percentiles were
8.5 and 1.0, respectively, and the steepest early slope was
66.0 ml/min per 1.73 m2 per year, observed in the patient
presented in Figure 1f. With Cox proportional hazards
models, we evaluated this early eGFR slope as a predictor of
time to ESRD during subsequent follow-up after the initial
period used for estimating the early slope. We compared its
performance with that of common clinical risk indicators:
albumin to creatinine ratio (ACR), glycated hemoglobin
(HbA1c) and systolic blood pressure. The early eGFR slope
was strongly associated with time to ESRD (Po0.0001). With
a C-index of 0.77 (95% confidence interval 0.70, 0.84), it was
a stronger predictor than traditional risk indicators: ACR,
HbA1c, and systolic blood pressure, singly or in combination
(Table 3).
Prognostic criteria for early eGFR slope
To determine simple criteria suitable for assigning an ESRD
risk to values of the early eGFR slope, we searched the
range of early eGFR slopes for cut-points (thresholds) that
Table 2 | Distribution of trajectories of eGFR changes
according to the presence of nonlinearity, significant decline,
and the direction of slope change for nonlinear patterns
N Percent
A. Linear 110 68.3
Stable (Figure 1a and b) 59 36.6
Declinea (Figure 1d and f) 51 (20)b 31.7
B. Clinically inconsequential nonlinearity 24 14.9
Stable (Figure 1c) 16 9.9
Declinea (Figure 1e) 8 (8)b 5.0
C. Clinically consequential nonlinearity 27 16.8
Deceleration (Figure 1g) 20 (2)b 12.4
Acceleration (Figure 1h and i) 7 (3)b 4.4
Abbreviations: eGFR, estimated glomerular filtration rate; ESRD, end-stage renal
disease.
Criteria for classifying trajectories as nonlinear and of clinical consequence are in
Materials and Methods.
aAn eGFR decline of 3.5ml/min per 1.73m2 per year or more.
bNumber of individuals reaching ESRD.
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Figure 2 |Distribution of slopes of eGFR decline according to
2ml/min intervals in 244 subjects with proteinuria (large
figure). The three patients in the intervalo32 had slopes 52.5,
56.4, and70.5ml/min per 1.73m2 per year (inset: the distribution
of slopes in the subset of 112 patients with linear trajectories of
eGFR decline). eGFR, estimated glomerular filtration rate.
Table 3 | Associations of the early slope of eGFR decline in
CKD stages 1–2 and of known risk factors with the risk of
ESRD
Model Predictor
Hazard
ratioa P-value C-index
1 Slope of early decline 1.31 (1.18, 1.44) o0.0001 0.77 (0.70, 0.84)
2 Urinary ACR 1.30 (1.05, 1.60) 0.015 0.72 (0.64, 0.80)
3 Hemoglobin A1c 1.43 (1.18, 1.73) 0.0003 0.69 (0.62, 0.76)
4 Systolic blood
pressure
1.06 (0.74, 1.54) 0.69 0.51 (0.40, 0.62)
5 BMI 0.79 (0.54, 1.15) 0.22 0.53 (0.43, 0.63)
6 ACE-I or ARB
treatment
0.67 (0.39, 1.17) 0.16 0.59 (0.51, 0.66)
7 Smoking 1.55 (0.79, 3.02) 0.20 0.56 (0.48, 0.64)
8 Model 2+3 — — 0.72 (0.65, 0.79)
9 Model 8+ slope — — 0.80 (0.73, 0.86)
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ACR, urinary albumin
to creatinine ratio; ARB, angiotensin receptor blocker; BMI, body mass index; CKD,
chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage
renal disease; hemoglobin A1c, glycated hemoglobin A1c.
aHazard ratio are expressed for 5ml/min per 1.73m2 per year change in slope,
1000mg/g increase in ACR, 1% increase in HbA1c, 20mmHg increase in blood
pressure, and 5-unit increase in BMI. For ACE-I or ARB treatment status, or smoking
the effect of ‘present’ vs. ‘absent’ is shown.
Only variables significant in univariate analysis enter models 8 and 9. The strength of
prediction of each model, in terms of discrimination, is described by C-index, where
a value 0.5 indicates a useless marker and 1.0 is perfect risk discrimination.
Data are point estimate (95% confidence interval).
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produced the maximum separation of the risk of ESRD for
two resulting groups, measured by the w2 for a log-rank test.
For this analysis, the time to ESRD was measured from the
last observation used to estimate the early eGFR slope. A cut-
point of 11 ml/min per 1.73 m2 per year produced the
largest separation, cumulative risk of 50.2% for those with
steeper eGFR declines and 7.0% for those with shallower
declines (Figure 3). As a screening test to diagnose patients
who would reach ESRD within 5 years, its sensitivity was 65%
and specificity 90%. Repeat the application of this procedure
to the range of slopes less steep than the cut-point of 11 ml/
min per 1.73 m2 per year yielded a second cut-point of
6.5 ml/min per 1.73 m2 per year. The cumulative risk at 5
years for the middle range (11 to 6.5 ml/min per 1.73 m2
per year) was 18.4% and was only 3.6% for the shallowest
slopes (Figure 3). Viewed as a screening test to distinguish
patients who will remain free of ESRD for 5 years, this cut-
point has a sensitivity of 75% and a specificity of 84%.
DISCUSSION
In this study of patients with proteinuria due to T1D, we
determined the trajectory of each individual’s change in
eGFR from its initially normal value for up to 18 years. We
found that the majority of these trajectories are well
represented by a simple regression line. Renal function was
stable throughout follow-up in approximately a third of the
patients, suggesting that their lifetime risk of ESRD is very
low. In the remaining two-thirds of the patients, renal
function declined significantly, but at rates that vary widely
among individuals. Observed times to the onset of ESRD
ranged from 1.3 to 17.3 years. These results invite
consideration of both the nature of the determinants of the
variation among individuals in the rate of eGFR decline and
the feasibility of developing means of predicting time to
ESRD in patients with T1D and proteinuria.
These findings in patients with T1D and proteinuria can be
considered as an extension of our previous study of renal
function loss in T1D patients with a milder abnormality of
urinary albumin excretion, microalbuminuria.11–13 In that
4- to 12-year follow-up study, we used serial measurements of
serum cystatin C to examine the trajectories of eGFR changes.
Significant renal function loss developed in one out of three
patients. Initially, renal function was either normal or even
elevated, and then began to decline at the onset of
microalbuminuria. The rate of loss was highly variable among
individuals, yet remained constant within individuals.11 In
this study of T1D patients with normal renal function and
proteinuria, significant renal function loss occurred in two
out of three patients during the 5–18 year of follow-up. As in
the previous study, the rate of loss was highly variable among
individuals, yet remained constant within individuals.
The mechanisms that initiate renal function decline in
patients while function is still normal are unknown. Also
uncertain is whether those initial mechanisms remain in
operation as renal function decline progresses through
advanced CKD stages. The ‘final common pathway’ hypoth-
esis posits two phases of renal function decline.14,15
Regardless of the nature of the initial injury, a shift in
pathology occurs at a certain point that is self-propelling and
possibly accelerating. As noted above, however, the majority
of patients experiencing eGFR decline in this study main-
tained a constant rate of loss as they passed from CKD stages
1 and 2 (early eGFR decline) through stages 3 and 4 (late
eGFR decline).
eGFR decline
–11
eGFR decline
< –11
eGFR decline
–6.5
eGFR decline
<–6.5
n =177
n =216
100%
50%
0%
0 2 4 6
Years
5-year CI of ESRD = 7.0%
n =143
100%
50%
0%
0 2 4 6
Years
5-year CI of ESRD = 3.6%
n =34
100%
50%
0%
0 2 4 6
Years
100%
50%
0%
0 2 4 6
Years
5-year CI of ESRD = 18.4%
n =39
5-year CI of ESRD = 50.2%
5-year CI of ESRD = 15.9%
100%
50%
0%
0 2
Years
4 6
Figure 3 |Cumulative incidence of ESRD according to various cut-points of slopes of early eGFR decline in ml/min per 1.73m2 per
year. Cumulative incidence (CI) of ESRD is presented according to years of follow-up after the last measurement used to estimate early
eGFR slope. eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
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A few hypotheses can be offered to explain an overall
pattern that includes a constant rate of decline within
individuals and large variability of that rate among
individuals. First, the process underlying loss must be fully
developed when it is initiated and usually does not evolve
over time. Although its initiation is likely triggered by
environmental factors, the constant rate of decline is most
likely the effect of constitutional susceptibilities such as
genetic factors. If the latter is true, multiple genes and
probably multiple variants within genes are likely required to
account for the large differences among individuals in the
rate of eGFR decline (Figure 2). Dissection of the genetic
architecture of diabetic nephropathy will best be achieved by
studies of the rate of eGFR as a quantitative phenotype rather
than by case–control studies.
The patients with T1D and proteinuria in the present
study had earlier been the members of the population of
T1D patients with microalbuminuria. They comprise two
major subpopulations: (1) those in whom early renal
function decline was already present when they entered this
study population, and (2) those whose renal function
remained normal and stable as albumin excretion pro-
gressed to proteinuria. The subpopulation with stable renal
function is much larger than generally perceived, and this
finding must be conveyed to physicians so they can advise
patients more appropriately that not all patients with
proteinuria are at high risk of ESRD. Diagnostic tools
(serum or urinary biomarkers or DNA sequence variants)
that distinguish patients with declining renal function
from those with stable function are highly desirable. Until
such tools become available, we propose that serum
creatinine be measured frequently in T1D patients with
proteinuria. These measurements can be used to estimate
the early eGFR slope, which appears to be a stronger
predictor of the risk of ESRD than other clinically available
characteristics.
Whether estimates of the slope of early eGFR decline can
be clinically useful for predicting the precise time for
initiating renal replacement therapy well in advance remains
to be evaluated. In the meantime, however, it can be
used to stratify subjects according to ESRD risk and urgency
for intervention. Clinical trials of progressively more
invasive or drastic therapies to prevent or postpone ESRD
become feasible if such patients can be selected and that their
risk of ESRD outweighs the associated discomfort and
complications.
We used eGFR determinations made before CKD stage 3
and within a maximum of 5 years of follow-up. The actual
follow-up time used to estimate the slope was shorter than 5
years for fast decliners who reached CKD stage 3 early. With
denser and more equally spaced eGFR determinations, it is
potentially possible to improve the predictive performance of
the early eGFR slope or reduce the observation time required
to obtain a satisfactory estimate of the slope. This issue
requires prospective investigation with an appropriate study
design.
Another potential application of the slope of early eGFR
decline would be its development and validation as a
surrogate outcome measure. Currently, evaluations of novel
therapies to prevent ESRD focus on individuals with
significantly impaired renal function. Quite likely, trial
interventions that retard the rate of renal function decline
will be less effective in patients with already impaired renal
function than in those at earlier disease stage. Thus, the slope
of early eGFR changes deserves evaluation as a candidate for
ESRD surrogate marker.
Most of the literature on trajectories of eGFR leading to
ESRD has focused on small groups of decliners, predomi-
nantly nondiabetic, who already had significantly impaired
renal function. The slope of renal function decline was
constant in the majority of studies,4–8,16 suggesting the
feasibility of predicting of the ESRD onset from serial renal
function estimates from early stages of CKD. Some authors
questioned this conclusion10,17 but also noted that, for the
majority of subjects, predicted times to ESRD from linear and
nonlinear models differed by less than a year.10
We studied patients with normal renal function and fitted
linear and spline models to their trajectories of eGFR
changes.9,10 Our conclusion of the predominance of linear
eGFR trajectories is robust given our relatively non-stringent
statistical criteria for rejecting linearity. Instead of greater
stringency, we supplemented statistical criteria with criteria
based on the clinical consequences of discrepancies between
linear and nonlinear models.
Although our study has many strengths, we acknowledge
real and perceived limitations. First, the prevalence of
treatment with angiotensin-converting enzyme inhibitors
and/or angiotensin receptor blockers at enrollment was lower
than currently prescribed. This was because ascertainment of
the cohort started in the early 1990 s when the use of
angiotensin-converting enzyme inhibitors was just coming
into vogue. The prevalence of angiotensin-converting enzyme
inhibitor and angiotensin receptor blocker treatment
increased from 56% in 1991–1995 to 82% in 2001–2004.
Noteworthy is the observation that despite this increase in
use of renin–angiotensin system blockade, the risk of ESRD
was unchanged and remains high.1 Moreover, renin–angio-
tensin system blockade was not associated with the slope of
renal function decline or the probability of deceleration of
decline. It has been suggested that the renin–angiotensin
system blockade, although has proven efficacy in a number of
trials, may not be sufficiently effective in a clinical setting.18
Second, we recruited proteinuria cases with normal renal
function. As this group included prevalent as well as incident
cases of proteinuria, and non-decliners accumulate among
prevalent cases, the proportion of non-decliners is higher
than would be found if all patients were incident cases.
Furthermore, our study included only patients with protei-
nuria due to diabetes. It is not clear that the findings would
be the same in patients without diabetes. Finally, we did not
have direct measurements of GFR in our study. However,
direct methods of measuring GFR have their own limitations.
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For example, as clearly demonstrated in Pima Indians,19
iothalamate clearance is affected by enormous intra-day
variations within an individual, a characteristic that limits the
value of direct determinations of GFR in estimating the slope
of renal function decline.
In summary, the predominantly constant rate of eGFR loss
observed in this study through all stages of CKD suggests that
this process is, to a large extent, predictable and that the risk
of ESRD can be reasonably well inferred from the early
slopes of eGFR changes over a 5-year period of observation.
The early eGFR slopes calculated under the linearity
assumption carry sufficient information for reliable risk
stratification. Further research on the determinants and
mechanisms of early renal function decline in patients with
T1D and proteinuria is necessary to develop new therapies to
reduce the risk of ESRD.1
MATERIALS AND METHODS
Population
Patients in this study are members of the Joslin Proteinuria Cohort
(n¼ 423). Informed consent procedures and protocols for patient
examinations at study entry and during follow-up were approved by
the Joslin IRB, as were methods for ascertaining all cases of ESRD or
death during 5–18 years follow-up. Details of these methods and
description of the natural history of the development of ESRD in
this cohort have been published.1
Assessment of proteinuria
The diagnoses of proteinuria were made in random urines by
determinations of the urinary ACR or meter readings of
Multistix test strips (Ames, Miles Laboratories, Elkhart, IN).
Proteinuria is diagnosed if the ACR (in mg/g) is X250 in men or
355 in women, or the Multistix reading is X2þ (corresponding to
albumin concentration E1000mg/ml) in two out of three
consecutive urine samples. A higher ACR is required for women
due to their lower creatinine concentrations. When calibrated
to timed measurements of albumin excretion, these sex-specific
ACR criteria are equivalent to an albumin excretion rate of
300mg/min.20
Albumin was measured by immunonephelometry on a BN100
with N Albumin kits (Behring, Somerville, NJ), with intra-assay and
inter-assay coefficients of variation o3 and 5%, respectively.
Creatinine measurements were assayed by Jaffe’s modified picrate
method on a Ciba Corning Express Plus Chemistry Analyzer
(Medfield, MA) (inter- and intra-assay coefficients of variation 2.3
and 3.5%, respectively). Separate from the determinations used for
the diagnosis of proteinuria, the urinary ACR was determined in a
sample obtained at the baseline examination of all patients.
Assessment of renal function
We used serum creatinine concentration and the Chronic Kidney
Disease Epidemiology Collaboration formula21 to estimate renal
function (eGFR) at study entry and during follow-up. In 2009,
serum creatinine was measured in all 1379 stored study samples (423
from baseline and 956 from follow-up examinations) at the
University of Minnesota using the Roche enzymatic assay (product
no. 11775685) on a Roche/Hitachi Mod P analyzer (Indianapolis,
IN). This method is calibrated to be traceable to an isotope dilution
mass spectrometry reference assay and was verified by measuring
National Institutes of Standards and Technology Standard Reference
Material (NIST SRM) no. 967.
We retrieved 4567 measurements of serum creatinine performed
in the 423 patients during routine clinic visits from the Joslin
Clinical Laboratory records. These measurements were assayed by
Jaffe’s modified picrate method on a Ciba Corning Express Plus
Chemistry Analyzer (inter- and intra-assay coefficients of variation
2.3 and 3.5%, respectively). For 1133 (24.8%) samples, the clinical
measurement was made on the same blood draw as that of the
measurement at the University of Minnesota because the routine
visit coincided with a study examination. We used these duplicate
measurements to calibrate the clinical measurements to the assay
method of the reference laboratory.
The onset of ESRD was determined by matching the study roster
against the United States Renal Data System and recorded as the
date of first renal transplant or dialysis, as described previously.1
Study group
To characterize the complete trajectories of eGFR decline from
normal to ESRD, we restricted this study to the 244 patients in the
Joslin Proteinuria Cohort, whose renal function was normal at
study entry (eGFRX60 ml/min per 1.73 m2). For these participants,
2955 follow-up measurements of serum creatinine (calibrated
to the reference laboratory) were available to trace the course of
eGFR over time.
Trajectories of eGFR decline during follow-up
We followed an approach described by Jones and Molitoris9 and
used by Shah and Levey10 to model an individual’s serial estimates of
renal function. A minimum of five observations is required,9 so only
161 (66.0%) of our study group and their 2723 eGFR determina-
tions were used. The approach represents each patient’s renal
function trajectory as a simple linear model and as a spline model
with linear segments connected at a point determined by a search
for minimum residual sum of squares. Our modification was to
allow more than two segments (three segments were required in two
patients and five segments in one individual). The spline and linear
models were compared, and a linear model was rejected at a
nominal significance of 0.05 and degrees of freedom determined by
the number of spline segments (n1).
Selection of a cut-point to distinguish stable from declining
trajectories was necessarily somewhat arbitrary. Practical considera-
tions support a decline of 3.5 ml/min per 1.73 m2 as a reasonable
choice. For an individual with this rate of decline and a beginning
eGFR of 95 ml/min per 1.73 m2 (the mean in our study group), 10
years would be required to reach CKD stage 3 and 25 years to reach
ESRD. This choice also has some empirical support. Studies in the
general population reported mean slopes of renal function decline
between 0.5 and 2.5 ml/min per 1.73 m2 per year.22–27 We
assumed a mean age-related decline of 1.0 ml/min per 1.73 m2 per
year as other authors have28,29 and a standard deviation of 2.0, as
extracted from published reports.22–27 If the distribution is normal,
the 10th percentile of distribution of eGFR slopes would be 3.5 ml/
min per 1.73 m2 per year.
All individuals with stable renal function were considered well
characterized by a linear model of renal function changes, as
deviations from linearity in overall non-declining trajectory are of
little clinical consequence. In decliners we considered over 1-year
difference between observed time of ESRD and time of reaching
eGFR¼ 10 ml/min per 1.73 m2 (expected time of ESRD) under
linear model as clinically consequential.
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Inter-individual variation in slope of eGFR decline
To estimate and describe inter-individual variation in the slope of
eGFR decline, we extracted the linear component of every subject’s
trajectory in the complete cohort of 244 individuals, including the
83 with less than five measurements. The onset of ESRD was
typically not accompanied by a measurement of serum creatinine in
the Joslin Clinic laboratory. Therefore, we assumed the eGFR was
10 ml/min per 1.73 m2 at that time.
Prediction of ESRD from the early slope of eGFR decline
When a patient presents clinically with T1D, normal renal function,
and proteinuria, the eGFR is monitored. After 5 years, the early
slope of eGFR values can be determined. To mimic this situation, we
estimated the early slope during the first 5 years of follow-up, while
patients remained in CKD stages 1 or 2 (eGFR X60 ml/min per
1.73 m2), and investigated its potential as a predictor of progression
to ESRD from that point during subsequent follow-up. The analysis
was restricted to patients with at least two serum creatinine
measurements (n¼ 216) before reaching their fifth enrollment
anniversary or CKD stage 3. We compared its performance as a
predictor with that of common clinical risk indicators: ACR, HbA1c,
and systolic blood pressure in Cox proportional hazards models
using the C-index, a generalized discrimination index for survival
data, as defined by Harrell et al.30
Statistical methods
Statistical significance was set at a P-value o0.05. Analyses were
conducted in SAS for Windows, version 9.2 (SAS Institute, Cary,
NC). Characteristics of patients were summarized by percentages,
means and standard deviations, or medians and quartiles. The linear
component of renal function trajectories was estimated with linear
regression, and linear spline models were fitted with least squares
method, as proposed by Jones and Molitoris7 and extended to allow
for multiple knots. The cumulative risk of ESRD was estimated by
the Kaplan–Meier method. Predictive performance of early eGFR
slope and clinical markers was evaluated with C-index30 in simple
and multiple Cox proportional hazards models. We then searched
the range of early slopes of eGFR decline for cut-points (thresholds)
that produced the maximum w2 (log-rank test) for the separation
between survival curves for the two resulting groups, as proposed by
Contal and O’Quigley.31
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